NationsBenefits Acquires Good Measures to Advance Food-as-Medicine Offerings
To ramp up its food-as-medicine support, NationsBenefits has acquired Good Measures, a company that offers coaching and personalized food prescriptions.
Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec
Halozyme’s offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition
Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson.
Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
Lundbeck says Longboard Pharmaceuticals’ drug, bexicaserin, has potential applications in a range of rare epilepsies. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome.
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion.
Hospital M&A Activity Remained Strong In Q2, Kaufman Hall Says
The number of hospital M&A deals may have fallen from Q1 to Q2 of this year, but that doesn’t mean that the hospital M&A space is lacking vitality, according to a new Kaufman Hall report. Rather, it means that the hospital M&A is shifting its emphasis from scale to strategy.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal
Eli Lilly’s Morphic acquisition brings an oral small molecule that blocks the same target as Entvyio, an injectable inflammatory bowel disease drug from Takeda Pharmaceutical. The Morphic deal follows Lilly’s 2023 acquisition of Dice Therapeutics, another company developing oral immunology medications.
At BIO, Novo Nordisk’s Top Dealmaker Talks M&A Strategy and What’s Next After GLP-1s
Novo Nordisk’s focus on diabetes and obesity shape its business development work, but the company is also exploring other areas. Top Novo Nordisk M&A executive John McDonald discussed his company’s strategy during a session at the BIO conference in San Diego.
Cigna MA Sale to HCSC Could Still Clear Way for Humana Acquisition, Expert Says
Despite Cigna and Humana ditching their pursuits to combine in December, one industry expert believes there's still a chance after Cigna announced its plan to sell its Medicare Advantage business to Health Care Service Corp.
Deloitte: 7 Trends Shaping Healthcare and Life Sciences in 2024
AI, health equity and merger and acquisition activity are among the trends to watch in 2024, according to a recent report from Deloitte.
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
How Financial Pressures Are Shaping Hospital M&A Activity
Hospitals weathered one of their most challenging years in 2022, with median operating margins staying in the red throughout most of the year. Those money problems proved to be a major factor shaping last year’s M&A transactions — financial pressures influenced 28% of hospital M&A deals last year, up from 15% in 2022, a new report showed.
How Can Hospitals Make the Post-Merger Transition As Smooth As Possible?
Experts have predicted that 2024 will be an eventful year for hospital M&A activity. As the industry prepares for another big year, there are a few things that health system leaders involved in these deals should keep in mind to make the process as smooth as possible, according to DexCare CEO Derek Streat.
‘We’re Getting Closer and Closer To Bright Going Dark’: Molina Lowers Purchase Price for Bright Health Group’s MA Business
Molina Healthcare's purchase price of Bright Health Group's Medicare Advantage business has dropped from $600 million to $500 million. This will make it increasingly difficult for Bright Health to pay off its debts, one expert said.
Navigating a Successful M&A Integration Process
Integrations are incredibly destabilizing and stressful for impacted employees, as well as for those who “survive.” Organizations that are worth acquiring are successful and attractive because they are comprised of smart, talented people who have created that success.
Expert: The Rumored Humana/Cigna Combination Makes Sense
With Cigna mostly focused on the commercial market and Humana mostly focused on the Medicare Advantage market, the rumored combination rumors check out, according to one industry expert.